TP53 mutations determined by targeted NGS in breast cancer: a case-control study

Background: Tumor protein 53 (TP53) gene mutations are identified in up to 37% of breast tumors especially in HER-2 positive and basal-like subtype. Previous studies have indicated TP53 mutations as a prognostic biomarker in breast cancer. However, most of these studies performed immunohistochemistr...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrikopoulou, Angeliki, Terpos, Evangelos, Chatzinikolaou, Spyridoula, Apostolidou, Kleoniki, Ntanasis-Stathopoulos, Ioannis, Gavriatopoulou, Maria, Dimopoulos, Meletios-Athanasios, Zagouri, Flora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522843/
https://www.ncbi.nlm.nih.gov/pubmed/34676052
http://dx.doi.org/10.18632/oncotarget.28071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522843/
https://www.ncbi.nlm.nih.gov/pubmed/34676052
http://dx.doi.org/10.18632/oncotarget.28071

Ejemplares similares